The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations whe...

Descripció completa

Dades bibliogràfiques

Autors principals:	Chih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, Kuan-Li Wu, Ta-Chih Liu, Shah-Hwa Chou, Jui-Ying Lee, Jui-Sheng Hsu, Ming-Shyan Huang, Inn-Wen Chong
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2017-05-01
Col·lecció:	BMC Pharmacology and Toxicology
Matèries:	Epidermal growth factor receptor Gefitinib Acquired resistance Chemotherapy Erlotinib
Accés en línia:	http://link.springer.com/article/10.1186/s40360-017-0130-0
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!